Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 127.3%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 29,100 shares, an increase of 127.3% from the January 31st total of 12,800 shares. Based on an average trading volume of 70,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OCS. Bellevue Group AG purchased a new stake in shares of Oculis in the 4th quarter valued at $170,000. XTX Topco Ltd purchased a new stake in Oculis during the fourth quarter valued at about $225,000. Geode Capital Management LLC grew its stake in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Oculis in the fourth quarter worth about $389,000. Finally, Bank of America Corp DE lifted its stake in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after acquiring an additional 10,667 shares during the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on OCS shares. Chardan Capital reissued a "buy" rating and set a $28.00 price objective on shares of Oculis in a report on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Oculis in a research report on Monday, January 6th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $28.80.

Remove Ads

Oculis Price Performance

Shares of Oculis stock traded up $0.99 during trading on Wednesday, hitting $18.98. 53,123 shares of the stock traded hands, compared to its average volume of 44,394. The firm's fifty day moving average is $20.66 and its 200-day moving average is $16.63. The stock has a market cap of $768.77 million, a price-to-earnings ratio of -9.83 and a beta of -0.24. Oculis has a 52 week low of $10.55 and a 52 week high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.